Trial Profile
A Single-dose Dose Escalation Trial in a Randomised, Single-blind, Placebo-controlled Group-comparison Design to Investigate the Safety and Tolerability of XEN-D0501 in Patients With Diabetes Mellitus Type 2
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2020
Price :
$35
*
At a glance
- Drugs XEN D0501 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors PILA PHARMA
- 19 Mar 2019 Status changed from recruiting to completed.
- 25 Oct 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 25 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2018.